Insight Molecular Diagnostics ROA 2014-2025 | IMDX
Current and historical return on assets (ROA) values for Insight Molecular Diagnostics (IMDX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Insight Molecular Diagnostics ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-06-30 | $-0.06B | $0.05B | -118.52% |
| 2025-03-31 | $-0.06B | $0.06B | -98.33% |
| 2024-12-31 | $-0.06B | $0.04B | -97.21% |
| 2024-09-30 | $-0.04B | $0.07B | -60.48% |
| 2024-06-30 | $-0.04B | $0.08B | -50.17% |
| 2024-03-31 | $-0.04B | $0.07B | -51.90% |
| 2023-12-31 | $-0.03B | $0.08B | -35.37% |
| 2023-09-30 | $-0.06B | $0.08B | -64.59% |
| 2023-06-30 | $-0.06B | $0.09B | -56.07% |
| 2023-03-31 | $-0.06B | $0.08B | -46.97% |
| 2022-12-31 | $-0.07B | $0.10B | -50.87% |
| 2022-09-30 | $-0.06B | $0.16B | -40.38% |
| 2022-06-30 | $-0.07B | $0.17B | -42.17% |
| 2022-03-31 | $-0.07B | $0.15B | -43.01% |
| 2021-12-31 | $-0.06B | $0.16B | -40.38% |
| 2021-09-30 | $-0.03B | $0.17B | -25.71% |
| 2021-06-30 | $-0.03B | $0.18B | -25.78% |
| 2021-03-31 | $-0.03B | $0.13B | -34.10% |
| 2020-12-31 | $-0.03B | $0.06B | -50.85% |
| 2020-09-30 | $-0.03B | $0.06B | -57.92% |
| 2020-06-30 | $-0.03B | $0.06B | -61.22% |
| 2020-03-31 | $-0.03B | $0.06B | -60.82% |
| 2019-12-31 | $-0.02B | $0.04B | -57.52% |
| 2019-09-30 | $-0.02B | $0.03B | -61.79% |
| 2019-06-30 | $-0.02B | $0.04B | -66.02% |
| 2019-03-31 | $-0.02B | $0.04B | -88.31% |
| 2018-12-31 | $-0.02B | $0.01B | -133.33% |
| 2018-09-30 | $-0.02B | $0.01B | -125.49% |
| 2018-06-30 | $-0.02B | $0.01B | -153.85% |
| 2018-03-31 | $-0.02B | $0.02B | -146.15% |
| 2017-12-31 | $-0.02B | $0.01B | -156.86% |
| 2017-09-30 | $-0.02B | $0.01B | -138.18% |
| 2017-06-30 | $-0.02B | $0.01B | -103.45% |
| 2017-03-31 | $-0.01B | $0.02B | -105.66% |
| 2016-12-31 | $-0.01B | $0.01B | -100.00% |
| 2016-09-30 | $-0.01B | $0.02B | -110.64% |
| 2016-06-30 | $-0.01B | $0.01B | -160.00% |
| 2016-03-31 | $-0.01B | $0.01B | -173.91% |
| 2015-12-31 | $-0.01B | $0.01B | -246.15% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.071B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.976B | 58.72 |
| Doximity (DOCS) | United States | $12.734B | 56.66 |
| Tempus AI (TEM) | United States | $12.722B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $9.947B | 81.50 |
| IRhythm Technologies (IRTC) | United States | $5.455B | 0.00 |
| Hinge Health (HNGE) | United States | $4.531B | 0.00 |
| Heartflow (HTFL) | $2.821B | 0.00 | |
| Inspire Medical Systems (INSP) | United States | $2.730B | 40.13 |
| Privia Health (PRVA) | United States | $2.669B | 197.73 |
| Phreesia (PHR) | United States | $1.904B | 0.00 |
| Enovis (ENOV) | United States | $1.773B | 9.37 |
| 10x Genomics (TXG) | United States | $1.745B | 0.00 |
| Omnicell (OMCL) | United States | $1.526B | 29.41 |
| Schrodinger (SDGR) | United States | $1.457B | 0.00 |
| Azenta (AZTA) | United States | $1.384B | 60.40 |
| Clover Health Investments (CLOV) | United States | $1.379B | 0.00 |
| Claritev (CTEV) | United States | $1.184B | 0.00 |
| Evolent Health (EVH) | United States | $1.130B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.662B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.542B | 0.00 |
| Veradigm (MDRX) | United States | $0.535B | 0.00 |
| Standard BioTools (LAB) | United States | $0.489B | 0.00 |
| Talkspace (TALK) | United States | $0.454B | 135.50 |
| Butterfly Network (BFLY) | United States | $0.395B | 0.00 |
| Carlsmed (CARL) | United States | $0.369B | 0.00 |
| TruBridge (TBRG) | United States | $0.302B | 52.95 |
| Health Catalyst (HCAT) | United States | $0.260B | 0.00 |
| Outset Medical (OM) | United States | $0.248B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.225B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.210B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.197B | 0.00 |
| CapsoVision (CV) | United States | $0.185B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.170B | 0.00 |
| CareCloud (CCLD) | United States | $0.157B | 7.13 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.122B | 0.00 |
| American Well (AMWL) | United States | $0.112B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.085B | 0.00 |
| Pulmonx (LUNG) | United States | $0.076B | 0.00 |
| 111 (YI) | China | $0.061B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.056B | 0.00 |
| HeartBeam (BEAT) | United States | $0.040B | 0.00 |
| Precipio (PRPO) | United States | $0.025B | 0.00 |
| Zhongchao (ZCMD) | China | $0.025B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.015B | 0.00 |
| PROFUSA (PFSA) | United States | $0.013B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.005B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |